FDA slaps gene therapy Elevidys with boxed warning after fatal liver failures
Elevidys came under scrutiny in June when the FDA disclosed two fatal cases in non-ambulatory boys who developed dangerously high liver enzyme levels
Elevidys came under scrutiny in June when the FDA disclosed two fatal cases in non-ambulatory boys who developed dangerously high liver enzyme levels
Topline results from the Phase 2 VISTA trial show that PIPE-307 did not meet its primary or secondary efficacy endpoints
Landmark studies have shown that rapid TXA administration can significantly reduce mortality
Innovent plans to soon submit a new drug application (NDA) to China’s National Medical Products Administration
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
According to the ICMR-INDIAB study, 11.4% of adults in India have type 2 diabetes, while a staggering 15.3% are pre-diabetic
The study successfully met its primary endpoint, demonstrating similar rates of viral suppression for DOR/ISL compared to Biktarvy at 48 weeks
Subscribe To Our Newsletter & Stay Updated